Cipla Limited , a prominent player in the Indian pharmaceutical industry, has recently received an Environmental, Social, and Governance (ESG) rating of 60 from ESG Risk Assessments & Insights Limited (ESGRisks.ai), a SEBI-registered ESG rating provider. This development marks a significant step in Cipla's commitment to sustainable and responsible business practices.

Rating Details and Disclosure

The company received communication about this rating on July 28, 2025, at 18:59 hours IST. In compliance with regulatory requirements, Cipla promptly disclosed this information to the stock exchanges.

Independent Assessment

It's important to note that the ESG rating was independently assigned by ESGRisks.ai, underlining the credibility and impartiality of the assessment. This independent evaluation provides stakeholders with an objective view of Cipla's performance in environmental, social, and governance aspects.

Regulatory Compliance

The disclosure of this ESG rating aligns with the Securities and Exchange Board of India (SEBI) regulations, specifically Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, it adheres to the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which likely pertains to ESG rating disclosures.

Implications for Investors

For investors and stakeholders, this ESG rating of 60 provides valuable insights into Cipla's performance and commitment to sustainable business practices. ESG ratings are increasingly becoming a crucial factor for investors who prioritize companies with strong environmental, social, and governance track records.

While the specific details of the ESG assessment criteria are not provided, the rating of 60 suggests that Cipla has made notable efforts in addressing ESG concerns. However, investors may want to compare this rating with industry benchmarks to gain a more comprehensive understanding of Cipla's relative performance in the ESG space.

As companies continue to face growing pressure to demonstrate their commitment to sustainability and responsible business practices, Cipla's proactive approach in obtaining and disclosing its ESG rating reflects its awareness of these evolving market expectations.

Cipla , a leading pharmaceutical company, saw its shares rally by 6% over two trading sessions, reaching Rs 1,575.00 following the release of impressive quarterly earnings. The company's strong performance and positive outlook have prompted several brokerages to revise their target prices upward.

Financial Performance

Cipla reported robust financial results for the quarter:

The company maintains a strong balance sheet with Rs 10,838.00 crore in cash reserves and a net cash position of Rs 10,379.00 crore.

Brokerage Outlook

Following the results, multiple brokerages have revised their target prices for Cipla:

• Antique: Maintained a Buy rating with the highest target price of Rs 1,875.00
• Nuvama: Raised its target to Rs 1,651.00 with a Hold rating
• Choice Broking: Upgraded to Add with a target of Rs 1,620.00

Future Prospects

Analysts have highlighted Cipla's strong product pipeline, particularly in respiratory products and inhalation therapy. Key upcoming launches include:

• gAdvair: Expected in FY26
• gSymbicort: Expected in FY27

Cipla has set an ambitious target of achieving $1 billion in US sales by FY27, underlining its growth strategy in the crucial North American market.

Market Response

The positive quarterly results and optimistic broker outlooks have contributed to the 6% surge in Cipla's share price over two trading sessions. Investors appear to be responding favorably to the company's financial performance and future growth prospects.

As Cipla continues to strengthen its position in the pharmaceutical industry, particularly in the respiratory segment, market observers will be closely watching the company's progress towards its US sales target and the successful launch of its pipeline products.